Ozempic, FDA and Chronic Kidney Disease

FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney disease, kidney failure, and cardiovascular death in patients treated with Ozempic.
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of
Ozempic is first GLP-1 drug FDA-approved for kidney disease
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes.
FDA approves Ozempic for kidney disease treatment in diabetes patients
The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, developed by pharmaceutical company Novo Nordisk (NYSE:NVO). The medication is now approved to lessen the risk of kidney disease progression,
FDA Approves Ozempic in Chronic Kidney Disease
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in kidney function, or death from kidney or heart causes, in diabetic patients with chronic kidney disease.
FDA Approves Ozempic to Reduce Kidney Disease in Type 2 Diabetes
Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common complication of type 2 diabetes.
Ozempic Receives New Indications in Chronic Kidney Disease
Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.
US FDA clears Ozempic for use in diabetics with chronic kidney disease: What does it mean for you?
It showed that 1 mg Ozempic led to a 24 per cent reduced risk of worsening kidney disease and kidney failure (end-stage kidney disease)
FDA clears use of Ozempic to protect kidney health
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, which hasn’t yet proven it can improve outcomes in kidney disease.
FDA OKs Ozempic for diabetic kidney disease
The FDA has approved Ozempic to reduce the risk of kidney disease worsening, kidney failure and cardiovascular-related death in adults with Type 2 diabetes and chronic kidney disease. This new approval expands Ozempic's use,
Daily21h
FDA approves Semaglutide for renal protection among diabetes patients with CKD
Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...